Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery

PHASE4TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Type 2 Diabetes MellitusCardiovascular Disease
Interventions
DRUG

Saxagliptin

one 5-mg saxagliptin tablet daily

DRUG

Placebo

5mg placebo tablet daily

Trial Locations (10)

23225

Chippenham Medical Center, Richmond

25304

Charleston Area Medical Center (CAMC), Charleston

27710

Duke University Medical Center (DUMC), Durham

30308

Emory University Hospital Midtown, Atlanta

35211

Cardiology, PC, Birmingham

35243

Cardio-Thoracic Surgeons PC, Birmingham

35801

Heart Center Research, LLC, Huntsville

72205

Arkansas Cardiology, PA, Little Rock

72901

Sparks Regional Medical Center, Fort Smith

94304

Stanford University Medical Center, Palo Alto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Duke University

OTHER